Alicia-Marie Conway

accessibility text

Name

Alicia-Marie Conway

Job title

Senior Clinical Lecturer and Honorary Medical Oncology Consultant

Email Address

lindsey.duncan1@nhs.net

Phone number

0161 446 8106

Qualifications

MBChB, MRes, MRCP (UK), MRCP (Medical Oncology), PhD

Specialities

Hepatobiliary (HPB), Neuroendocrine

Started at The Christie (Year)

2026

Responsibilities

Dr Conway is an honorary consultant medical oncologist treating patients with hepatobiliary and pancreatic malignancies and neuroendocrine neoplasms. Clinical responsibilities include inpatient care, outpatient NHS and research clinics, multi-disciplinary team meetings, clinical supervision and training and clinical trial investigator roles.

As a clinical academic at The University of Manchester, Dr Conway dedicates her non-clinical time to translational cancer research, working closely with the Cancer Research UK National Biomarker Centre.

Professional biography

Dr Conway graduated from The University of Manchester medical school in 2010, having completed an MBChB an intercalated Masters in Research in Viral Oncology. She completed general medical training in the North West of England, obtaining MRCP (UK) in 2013. She was accepted onto the academic specialist training programme in Medical Oncology in 2015, undertaken at The Christie NHS Foundation Trust.

Dr Conway completed her PhD at the CRUK National Biomarker Centre in 2022, developing a blood-based means of diagnosing cancer to improve the diagnosis and treatment of Cancers of Unknown Primary. This work was awarded the Association of Cancer Physicians Presidents Prize in 2022, an annual award offered to one UK medical oncology trainee for outstanding contribution to cancer research. Subsequently, Dr Conway obtained MRCP Specialist Certificate Examination in Medical Oncology in 2024, obtaining her Certificate of Completion of Training (CCT) and joining the specialist register in December 2026.

Research Interest

Liquid biopsies and translational research in Cancers of Unknown Primary, HPB malignancies and Neuroendocrine Neoplasms.

Publications